The FDA is considering revoking its approval for Pfizer’s COVID-19 vaccine for healthy kids under 5. This decision, if finalized, could leave many families without an option for their young children. Currently, other vaccines from Moderna and Novavax are approved for select groups, but not for all children.
While COVID-19 often causes mild symptoms in kids, infants and those with certain health issues are at higher risk. Reports suggest that about 1-2% of children with COVID-19 may require hospitalization, making vaccinations crucial for protecting vulnerable populations.
The FDA’s review isn’t about safety but revolves around ongoing discussions about authorizations. Pfizer is urging the FDA to keep the approval active for the upcoming fall and winter. They maintain that their vaccine is effective, with a favorable safety record.
This potential shift in vaccination policy follows changes in leadership at the Health and Human Services Department under Secretary Robert F. Kennedy Jr., known for his skepticism towards vaccines. This has sparked debate in the health community, with some experts expressing concern about the implications for public health.
In July, Moderna gained full approval for its vaccine, but only for children with certain medical conditions. Meanwhile, Kennedy’s recent actions—including a CDC update—have altered vaccine recommendations for children and pregnant women.
It’s essential to keep an eye on these developments as they can significantly impact child health and vaccination strategies in the U.S.
For more detailed information, check the CDC’s official guidelines.
Source link
Vaccinations,COVID-19,U.S. Department of Health and Human Services,Secretary of Health and Human Services,Breaking News: Business,Health care industry,Pharmaceuticals,Biotech and Pharmaceuticals,Biotechnology,Business,Pfizer Inc,Novavax Inc,Moderna Inc,Social issues,Robert F. Kennedy Jr.,United States,business news
